Calmare Therapeutics Incorporated reported earnings results for the third quarter ended September 30, 2014. For the period, the company reported revenue from the sale and shipment of the Calmare pain therapy devices for the quarter increased 28% or $110,000 to $400,000 as compared with $290,000 for the quarter ended September 30, 2013. Net loss for the quarter increased to $1,229,000 or $0.05 per basic and diluted share as compared with a net loss of $609,000 or $0.04 per basic and diluted share for the quarter ended September 30, 2013.